We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Comparative Effectiveness Unlikely to Influence FDA, May Affect CMS: Expert
Comparative Effectiveness Unlikely to Influence FDA, May Affect CMS: Expert
May 23, 2012
Drug sponsors may be able to relax a bit about an upcoming jump in comparative effectiveness research (CER) and its effect on FDA decisions.